ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $877,716 | -81.8% | 19,027 | -84.2% | 0.00% | -83.3% |
| Q1 2023 | $4,831,007 | +21.5% | 120,474 | +40.4% | 0.02% | +9.1% |
| Q4 2022 | $3,976,689 | +442.5% | 85,834 | +385.1% | 0.02% | +450.0% |
| Q3 2022 | $733,000 | -61.6% | 17,695 | -32.7% | 0.00% | -63.6% |
| Q1 2022 | $1,910,000 | -52.5% | 26,295 | -45.0% | 0.01% | -50.0% |
| Q4 2021 | $4,021,000 | +279.3% | 47,816 | +306.8% | 0.02% | +214.3% |
| Q3 2021 | $1,060,000 | -60.9% | 11,754 | -58.7% | 0.01% | -63.2% |
| Q2 2021 | $2,713,000 | +417.7% | 28,456 | +518.3% | 0.02% | +375.0% |
| Q1 2021 | $524,000 | -67.3% | 4,602 | -60.3% | 0.00% | -69.2% |
| Q4 2020 | $1,604,000 | +82.7% | 11,585 | +8.5% | 0.01% | +85.7% |
| Q3 2020 | $878,000 | -5.0% | 10,681 | -50.6% | 0.01% | -61.1% |
| Q4 2019 | $924,000 | -34.9% | 21,635 | +17.1% | 0.02% | -52.6% |
| Q2 2018 | $1,420,000 | – | 18,470 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |